Unlocking the power

of complex proteins for

future therapies

Unlocking the power

of complex proteins for

future therapies

Mission

We develop drug candidates to advance into the clinic with pharmaceutical partners

New solutions and new therapies need new avenues to reach them. The age of cells producing biological compounds has achieved a lot for human medicine, but its means are coming to an end. A step change in technology is required to unleash the potential of molecules we didn’t dream we would discover – or be able to create if we did.

ELEVA is opening this realm of unprecedented therapies with the help of an inconspicuous but incredibly efficient tool: Bryophyta, more commonly known as moss. This ancient organism holds the key to the therapies of the future. Moss plants are not only able to produce the most complex and demanding proteins; with their unique characteristics, they virtually invite easy, stable engineering and reliable output.

What we offer

How Eleva can change your world

We have harnessed the moss platform’s outstanding features to create candidates and take them to clinical stages, ready for a bright future. Be our clinical partner to develop unprecedented candidates into the therapies that will turn around countless patient’s lives.

  • Are you looking for a partner with an asset that might be the key to a revolutionary treatment?
  • Are you struggling with a difficult protein?
  • Are you toying with a revolutionary toxin that targets just the right cells?

Join us and our moss cells to unleash opportunities never imagined before, based on a platform that surpasses the capacities of all other cell lines used to date.

Talk to us if you are looking at producing

  • Antibodies
  • Biobetters
  • LSD enzymes
  • Fusion toxins
  • Virus-like particles/vaccines
  • Any complex, difficult protein
  • Efficient and effective glycosylation
Platform

Everything you expect from cell line development – yet without the problems

Tailored glycosylation

Tailored glycolysation

Flexible Genetic Engineering

Flexible genetic engineering

Pathogen-free processing

Pathogen-free processing

Fusion toxin production

Fusion toxin production

Business model​

At Eleva ...

We develop clinical assets in partnership with pharmaceutical companies

… we develop complex proteins into tomorrow’s drugs in partnership with pharmaceutical companies

We unlock the potential of difficult compounds that have so far failed to get expressed

… we unlock the potential of difficult compounds that have so far failed to get expressed

We explore unusual opportunities in other promising fields

… we explore unusual opportunities in other promising fields

We have successfully developed enzymes and other proteins into clinical stages and continue to scout for promising compounds. This results in a plethora of opportunities. Whilst our technology platform remains the property of Eleva, new individual assets will be developed in cooperation with pharmaceutical partners. Each of such partnerships will be taken into a newly formed subsidiary. This allows the partners to focus on the respective indication.

Our Pipeline

We are inviting pharmaceutical partners to take all current and future candidates to clinical success.

Indication

 

C3 glomerulopathy (C3G)

 

Complement disorders

 

Complement disorders

Research

Preclinical

Phase I

Phase II

Compleva FH /CPV-101 (natural complement regulator)

Compleva MFHR1/CPV-102 (novel multi-level complement regulator)
Compleva FHL/CPV-103 (natural complement regulator)

Indication​ C3 glomerulopathy (C3G)

Compleva FH/CPV-101 (natural complement regulator)

Research

Preclinical

Phase I

Phase II

Indication complement disorders

Compleva MFHR1/CPV-102 (novel multi-level complement regulator)

Research

Preclinical

Phase I

Phase II

Indication complement disorders

Compleva FHL/CPV-103 (natural complement regulator)

Research

Preclinical

Phase I

Phase II

 

Fabry disease

 

Pompe disease

Repleva AGAL/RPV-001 (glyco-improved Fabry-ERT)

Repleva GAA/RPV-002 (glyco-improved Pompe-ERT)

Indication Fabry disease

Repleva AGAL/RPV-001 (glyco-improved Fabry-ERT)

Research

Preclinical

Phase I

Phase II

Indication Pompe disease

Repleva GAA/RPV-002 (glyco-improved Pompe-ERT)

Research

Preclinical

Phase I

Phase II

News

Eleva secures up to EUR 60 million to advance a drug candidate, appoints new board member

January 6, 2021 Press Release

Eleva, a manufacturer of superior biologics, is exploring the potential of one of its drug candidates for first-in-line therapy of Covid-19. The compound, factor H, is part of the complement system, which is believed to affect the severity of the course of Covid-19. Eleva has developed factor H previously for a different indication and taken it through pre-clinical stages.

READ MORE

Navigo Proteins and Eleva Announce Successful Development of an Affinity Chromatography Resin Customized for the Efficient Purification of Human Complement-Factor H

March 16, 2021 Press Release

Custom Affinity Chromatography Resin Promises High Yield Purification in Clinical and Commercial GMP Downstream Processing.

READ MORE

Eleva’s drug candidate to be examined for use in Covid-19 treatment

June 3, 2020 Press Release

Eleva, a manufacturer of superior biologics, is exploring the potential of one of its drug candidates for first-in-line therapy of Covid-19. The compound, factor H, is part of the complement system, which is believed to affect the severity of the course of Covid-19. Eleva has developed factor H previously for a different indication and taken it through pre-clinical stages.

READ MORE

Contact

We look forward to hearing from you! 

eleva GmbH
Hans-Bunte-Str. 19
79108 Freiburg
Germany

Phone: +49 761 470 99 0
hello@elevabiologics.com

Follow us

I consent to the processing of my personal data for the purpose of establishing contact in accordance with Article 6 paragraph 1 lit a of the Basic Data Protection Regulation (DSGVO). I consent to the processing of my personal data for the purpose of establishing contact in accordance with Article 6 paragraph 1 letter a of the Basic Data Protection Regulation (DSGVO).

In accordance with Article 13 of the Basic Data Protection Regulation (DSGVO), we would like to provide you with comprehensive information about the processing of your personal data. You can read all relevant information in our data protection policy.

eleva GmbH

Hans-Bunte-Str. 19
79108 Freiburg, Germany

Phone: +49 761 470 99 0
hello@elevabiologics.com

Contact · Imprint · Privacy Policy

© 2021 eleva GmbH

eleva Newsletter